{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:02:18Z","timestamp":1780038138471,"version":"3.53.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study evaluated the efficacy of TiaoPi AnChang Decoction (TPACD) against CAPOX-induced adverse reactions (CIARs) and improving survival outcomes in colorectal cancer (CRC) patients receiving CAPOX as adjuvant chemotherapy. This paper presents an interim analysis of the clinical trial, with a primary focus on CIARs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This was a randomized, double-blind, placebo-controlled trial enrolling high-risk stage II or III CRC patients undergoing CAPOX who were diagnosed with spleen-kidney deficiency syndrome. The study planned to randomly assign 98 patients in a 1:1 ratio to either the TPACD group (30\u00a0mL orally, twice daily) or the placebo group (matched placebo). The trial duration spanned 4 chemotherapy cycles (approximately 84 days), during which we assessed the incidence of CIARs (graded via CTCAE), Traditional Chinese Medicine (TCM) syndrome scores, quality of life (QoL, evaluated via EORTC QLQ-C30), peripheral blood immune cell subsets, tumor markers, safety, and survival outcomes. A linear mixed-effects model was applied to adjust for baseline differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 496 screened CRC patients, 108 were randomized into the TPACD group (n = 54) or the placebo group (n = 54). The incidence of overall CIARs was significantly lower in the TPACD group (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.009), particularly for grade \u22652 CIARs (37.77% vs. 67.70%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.008). Subgroup analyses revealed that the treatment effect was homogeneous, with no significant interaction observed between the treatment and the variables of age, sex, BMI, tumor size, or TNM stage (all\n                      <jats:italic>P<\/jats:italic>\n                      for interaction &amp;gt;0.05). TPACD administration resulted in improvements in symptoms including fatigue, nausea, vomiting, loss of appetite, and oxaliplatin-induced peripheral neuropathy. However, its efficacy in alleviating myelosuppression, hand-foot syndrome, and pain was limited. Additionally, TPACD improved overall QoL (least squares mean difference (LSMD) \u221211.71,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), attenuated the progression of spleen-kidney deficiency syndrome (LSMD 3.09,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), and positively influenced the CD4+\/CD8+ ratio (1.91 \u00b1 0.94 vs. 2.64 \u00b1 1.04,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002). No additional hepatic or renal injury was observed. The predefined endpoints for survival outcomes had not been reached at the time of this analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TPACD serves as an effective, safe, well-tolerated, and readily acceptable complementary therapy for CRC patients undergoing CAPOX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.chictr.org.cn\/index.html<\/jats:ext-link>\n                      , identifier ChiCTR2200065759.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1707147","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:09:11Z","timestamp":1780034951000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of TiaoPi AnChang decoction to reduce CAPOX-Induced adverse reactions in Chinese patients with colorectal cancer: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Jincheng","family":"Zhang","sequence":"first","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Department of Integrated Traditional Chinese and Western Medicine Oncology, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantong","family":"Guo","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional Chinese and Western Medicine Oncology, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional Chinese and Western Medicine Oncology, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dakui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzheng","family":"Jie","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional Chinese and Western Medicine Oncology, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"B2","doi-asserted-by":"publisher","first-page":"tfae139","DOI":"10.1093\/toxres\/tfae139","article-title":"Brain mitochondrial damage attenuation by quercetin and N-acetyl cysteine: peripheral and central antiemetic effects","volume":"13","author":"Abolfazli","year":"2024","journal-title":"Toxicol. Res. (Camb)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/jco.2010.30.0855","article-title":"Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08","volume":"29","author":"Allegra","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1200\/jco.2017.76.0355","article-title":"Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III Colon cancer: Disease-Free survival results from a randomized, Open-Label, international duration evaluation of adjuvant (IDEA) France, phase III trial","volume":"36","author":"Andr\u00e9","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00520-020-05610-x","article-title":"The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy","volume":"29","author":"Andreyev","year":"2021","journal-title":"Support. Care Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/01635581.2012.670743","article-title":"Malnutrition is high and underestimated during chemotherapy in gastrointestinal cancer: an AGEO prospective cross-sectional multicenter study","volume":"64","author":"Attar","year":"2012","journal-title":"Nutr. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.16368\/j.issn.1674-8999.2021.10.452","article-title":"Regulating effect of Xiangsha Liujunzi decoction on Colon cancer bearing nude mice","volume":"36","author":"Bao","year":"2021","journal-title":"Acta Chin. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11655-016-2538-6","article-title":"A preparation model of Chinese medicine decoction placebo","volume":"23","author":"Bian","year":"2017","journal-title":"Chin. J. Integr. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14033\/j.cnki.cfmr.2024.15.006","article-title":"Effect of Xiangsha Liujunzi decoction combined with XELOX chemotherapy and Bevacizumab targeting therapy on short-term efficacy and tumor markers in patients with advanced Colon cancer","volume":"22","author":"Chen","year":"2024","journal-title":"Chin. For. Med. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.7326\/m16-2977","article-title":"CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration","volume":"167","author":"Cheng","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/ptr.6068","article-title":"Herbal medicine for hand-foot syndrome induced by fluoropyrimidines: a systematic review and meta-analysis","volume":"32","author":"Deng","year":"2018","journal-title":"Phytother. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"156393","DOI":"10.1016\/j.phymed.2025.156393","article-title":"Traditional Chinese medicine Chaiqinchengqi decoction for patients with acute pancreatitis: a randomized clinical trial","volume":"138","author":"Deng","year":"2025","journal-title":"Phytomedicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1007\/s12325-020-01419-6","article-title":"Patient burden and real-world management of chemotherapy-induced myelosuppression: results from an Online Survey of patients with solid tumors","volume":"37","author":"Epstein","year":"2020","journal-title":"Adv. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.suronc.2019.06.003","article-title":"Adjuvant chemotherapy in resected colon cancer: when, how and how long?","volume":"30","author":"Gelibter","year":"2019","journal-title":"Surg. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1081\/cnv-58878","article-title":"Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer","volume":"23","author":"Goldstein","year":"2005","journal-title":"Cancer Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III Colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"118576","DOI":"10.1016\/j.jep.2024.118576","article-title":"Integrating UHPLC-Q-TOF-MS\/MS, network pharmacology, bioinformatics and experimental validation to uncover the anti-cancer mechanisms of TiaoPi AnChang decoction in colorectal cancer","volume":"334","author":"Guo","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"117735","DOI":"10.1016\/j.jep.2024.117735","article-title":"Efficacy and safety of traditional plant-based medicines for preventing chronic oxaliplatin-induced peripheral neurotoxicity in patients with colorectal cancer: a systematic review and meta-analysis with core herb contribution","volume":"326","author":"Han","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/jco.21.01315","article-title":"Randomized, Double-Blind, phase III Study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE","volume":"40","author":"Hata","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B20","first-page":"437","article-title":"Clinical study of Tiaopi Anchang Recipe combined with XELOX chemotherapy in the treatment of postoperative colorectal cancer patients","volume":"38","author":"He","year":"2023","journal-title":"China J. Tradit. Chin. Med. Pharm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"953205","DOI":"10.3389\/fphar.2022.953205","article-title":"Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines","volume":"13","author":"Heinrich","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.3390\/nu6115327","article-title":"Antioxidant and antifatigue activities of Polygonatum Alte-lobatum Hayata rhizomes in rats","volume":"6","author":"Horng","year":"2014","journal-title":"Nutrients"},{"key":"B23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/jco.20.01330","article-title":"Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer","volume":"39","author":"Iveson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/cam4.4896","article-title":"Traditional Chinese medicines and capecitabine-based chemotherapy for colorectal cancer treatment: a meta-analysis","volume":"12","author":"Jiang","year":"2023","journal-title":"Cancer Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.3390\/ijms24076753","article-title":"Transient changes in serum CEA, CA19-9, CRP, YKL-40, and IL-6 during adjuvant chemotherapy and survival of patients with colorectal cancer","volume":"24","author":"Lehtom\u00e4ki","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11655-023-3558-7","article-title":"Chinese medicine combined with adjuvant chemotherapy for improving myelosuppression in colorectal cancer patients: a systematic review and network meta-analysis","volume":"30","author":"Li","year":"2024","journal-title":"Chin. J. Integr. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e7373","DOI":"10.1097\/md.0000000000007373","article-title":"A multidisciplinary team approach for nutritional interventions conducted by specialist nurses in patients with advanced colorectal cancer undergoing chemotherapy: a clinical trial","volume":"96","author":"Lin","year":"2017","journal-title":"Med. Baltim."},{"key":"B28","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/pon.5921","article-title":"What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis","volume":"31","author":"Luigjes-Huizer","year":"2022","journal-title":"Psychooncology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1142\/s0192415x20500019","article-title":"Effects of herbal medicines on pain management","volume":"48","author":"Luo","year":"2020","journal-title":"Am. J. Chin. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"129878","DOI":"10.1016\/j.ijbiomac.2024.129878","article-title":"Structural characterization and immunomodulatory activity of a water-soluble polysaccharide from Poria cocos","volume":"261","author":"Lv","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"120486","DOI":"10.1016\/j.jep.2025.120486","article-title":"Combined analysis of network pharmacology and transcriptomics deciphers the pharmacological mechanism of Huangqi Guizhi Wuwu decoction attenuates Oxaliplatin-induced peripheral neuropathy via regulating Sirt1","volume":"354","author":"Mao","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3969\/j.issn.1006-2084.2022.13.036","article-title":"Application progress of Xiangsha Liujunzi decoction in digestive System diseases","volume":"28","author":"Ni","year":"2022","journal-title":"Med. Recapitulate"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1007\/s00520-016-3373-1","article-title":"Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)","volume":"24","author":"Pachman","year":"2016","journal-title":"Support. Care Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/jco.2015.60.9107","article-title":"Capecitabine plus oxaliplatin compared with Fluorouracil\/Folinic acid as adjuvant therapy for stage III Colon cancer: final results of the NO16968 randomized controlled phase III trial","volume":"33","author":"Schmoll","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"115109","DOI":"10.1016\/j.ejca.2024.115109","article-title":"Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: a randomized clinical trial","volume":"213","author":"Sun","year":"","journal-title":"Eur. J. Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3969\/j.issn.1008-8849.2024.09.001","article-title":"Effects of decoction for regulating spleen and calming intestine on intestinal flora in irinotecan delayed diarrhea in mice","volume":"33","author":"Sun","year":"","journal-title":"Glob. Tradit. Chin. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.19540\/j.cnki.cjcmm.20241015.601","article-title":"Review, revision, and prospect of list of substances with both edible and medicinal values in China","volume":"50","author":"Sun","year":"2025","journal-title":"China J. Chin. Mater. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/jco.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3969\/j.issn.1674-1749.2024.03.005","article-title":"Effect of Tiaopi Anchang Decoction on the expression of miR-34a-5p and Notch1\/NF-KB in nude mice with liver metastasis of colorectal cancer","volume":"17","author":"Wang","year":"2024","journal-title":"Glob. Tradit. Chin. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/cac2.12639","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update","volume":"45","author":"Wang","year":"","journal-title":"Cancer Commun. (Lond)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3969\/j.issn.1673-7202.2025.09.013","article-title":"Mechanism of Tiaopi Anchang Decoction in enhancing the treatment of Colon cancer liver metastasis by regulating the gut Microbiota and remodeling the immune microenvironment","volume":"20","author":"Wang","year":"","journal-title":"World Chin. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"117853","DOI":"10.1016\/j.jep.2024.117853","article-title":"Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: a prospective randomized controlled trial","volume":"325","author":"Wu","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.16736\/j.cnki.cn41-1434\/ts.2021.18.014","article-title":"Current situation and industry prospect of homology of medicine and food material with function off Jianpi","volume":"27","author":"Xiao","year":"2021","journal-title":"Mod. Food"},{"key":"B44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13020-023-00849-y","article-title":"Efficacy and safety of traditional Chinese medicine for cancer-related fatigue: a systematic literature review of randomized controlled trials","volume":"18","author":"Yang","year":"2023","journal-title":"Chin. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3816\/CCC.2010.n.015","article-title":"Transient carcinoembryonic antigen elevations during adjuvant chemotherapy for colorectal cancer reflect the burden of residual micrometastatic disease","volume":"9","author":"Yau","year":"2010","journal-title":"Clin. Colorectal Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/jco.21.02628","article-title":"Final analysis of 3 versus 6 months of adjuvant Oxaliplatin and fluoropyrimidine-based therapy in patients with stage III Colon cancer: the randomized phase III ACHIEVE trial","volume":"40","author":"Yoshino","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1200\/jco.2011.36.4539","article-title":"Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses","volume":"29","author":"Yothers","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.21147\/j.issn.1000-9604.2022.02.01","article-title":"CSCO guidelines for colorectal cancer version 2022: updates and discussions","volume":"34","author":"Yuan","year":"2022","journal-title":"Chin. J. Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"154823","DOI":"10.1016\/j.phymed.2023.154823","article-title":"Pinellia ternata-containing traditional Chinese medicine combined with 5-HT3RAs for chemotherapy-induced nausea and vomiting: a PRISMA-compliant systematic review and meta-analysis of 22 RCTs","volume":"115","author":"Zhai","year":"2023","journal-title":"Phytomedicine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.13422\/j.cnki.syfjx.20220821","article-title":"Activating effect of effective components in medicinal and edible substances on human pregnane X receptor and cytotoxicity screening","volume":"28","author":"Zhang","year":"2022","journal-title":"Chin. J. Exp. Tradit. Med. Formulae"},{"key":"B51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3760\/cma.j.cn112152-20240119-00035","article-title":"Cancer incidence and mortality in China, 2022","volume":"46","author":"Zheng","year":"2024","journal-title":"Chin. J. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1707147\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:09:26Z","timestamp":1780034966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1707147\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":51,"alternative-id":["10.3389\/fphar.2026.1707147"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1707147","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1707147"}}